Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Non-Alcoholic Steatohepatitis Biomarkers Industry Expected To Reach By 2029, Starting From 2025 Levels?
The valuation of the non-alcoholic steatohepatitis biomarkers sector has experienced substantial, rapid expansion recently, projected to climb from $1.36 billion in 2024 to reach $1.68 billion in 2025, reflecting an impressive compound annual growth rate of 23.9%; this historical upward momentum is largely fueled by factors such as the prevalence of diabetes and metabolic syndrome, increased consciousness and organized detection initiatives, the inherent constraints associated with liver biopsy procedures, backing from regulatory bodies, a transition toward tailored medical treatments, and ongoing clinical investigations concerning NASH.
The market for non-alcoholic steatohepatitis biomarkers is projected to experience rapid expansion over the coming years, reaching a valuation of $3.81 billion by 2029, propelled by a compound annual growth rate (CAGR) of 22.6%; this anticipated surge during the projection timeframe stems from several factors, including the introduction of new treatment modalities, the wider application of tailored medicine strategies, increased efforts from patient support groups, the incorporation of multi-omics information, and improvements in how actively patients participate in their care, while key developments shaping this period will involve the utilization of virtual healthcare and off-site tracking, the deployment of cutting-edge diagnostic systems, increased worldwide partnerships in research endeavors, progress in the methods used to uncover biomarkers, the adoption of artificial intelligence (AI), and the inclusion of diagnostic indicators derived from imaging techniques.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
What Are The Drivers Pushing New Developments In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Anticipated escalation in liver cancer incidence is poised to stimulate the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers sector in the coming period. Liver cancer, characterized by the emergence of abnormal growths within the hepatic tissue, may originate directly in the liver (primary) or be the result of metastasis from distant sites (secondary or metastatic). NASH biomarkers serve crucial roles in managing liver cancer by aiding in early identification, tracking how the illness advances, evaluating the effectiveness of administered therapies, offering insights into patient prognosis, and potentially lessening reliance on invasive investigative techniques. To illustrate the scale of this issue, global figures from the World Cancer Research Fund, a non-profit entity based in the UK, indicated roughly 866,136 new liver cancer diagnoses in 2022, positioning it as the sixth most frequently occurring cancer worldwide. Consequently, the increasing rate of liver cancer cases directly fuels the market for NASH biomarkers.
What Are The Primary Types Of Segments Analyzed In The Non-Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkersmarket covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
What Long-Term Trends Will Shape The Future Growth Of The Non-Alcoholic Steatohepatitis Biomarkers Industry?
Innovation is rapidly becoming a dominant factor driving expansion within the market for non-alcoholic steatohepatitis biomarkers, prompting key industry players to concentrate on creating novel offerings to bolster their competitive standing. A salient example of this trend is the five-year exclusive licensing agreement established in October 2022 between GENFIT, a biopharmaceutical firm situated in France and operating at a late development stage, and LabCorp, a life sciences enterprise based in the United States; this pact grants LabCorp rights to GENFIT’s NIS4 technology, intended to facilitate the identification of individuals potentially suffering from at-risk non-alcoholic steatohepatitis (NASH). This sophisticated NIS4 methodology, which relies on multiple biomarkers, was specifically engineered to pinpoint patients afflicted with NASH who also exhibit moderate to severe fibrosis (F greater than 2), a condition often described as at-risk NASH, and under the terms of this arrangement, LabCorp assumes responsibility for creating and marketing a blood-based molecular diagnostic assay leveraging the NIS4 technology throughout both the United States and Canada, thereby expanding accessibility for clinicians.
Who Are The Primary Competitors In The Global Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Non-Alcoholic Steatohepatitis Biomarkers Industry?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Non-Alcoholic Steatohepatitis Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2025, By The Business Research Company
Site Remediation Consulting Services Global Market Report 2025
Psoriasis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Scientific Research And Development Services Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model